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demonstrated a more clinically relevant and statistically 
significant difference, that is, patients with depresse d 
systolic function who require a more prolonged period 
of cardioplegic ischemic arrest. The findings of their 
study are without dispute; the population studied and 
the tools with which they were studied could have been 
chosen differently to determine the true effect of anti- 
oxidant supplementation sublethal myocardial injury 
in patients undergoing cardioplegic ischemic arrest. 
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Reply to the Editor." 
We thank Drs. Wait and Grayburn for their interest and 
for raising the important question of sublethal myocardial 
injury in patients undergoing cardioplegic schemic arrest. 
We used clinically important markers of irreversible myo- 
cardial injury to determine the antioxidant protective 
effect of c~-tocopherol and ascorbic acid, and we did not 
specifically examine the possibility of a beneficial but 
lesser effect on functional impairment ("stunning"). How- 
ever~ there are very few "perfect" measures of postoper- 
ative function and many are open to one criticism or 
another. The inotropic requirement is a "soft" measure 
and can vary markedly depending on the concomitant 
degree of volume administered, the depth of anesthesia or 
postoperative s dation, and the particular guidelines for 
blood pressure and filling pressures regarded as accept- 
able in that hospital. In fact, very few patients in this study 
required any inotropic support in the postoperative pe- 
riod. 
We agree that further studies should look for more 
subtle effects; however, if the antioxidant effects are small 
and transient, he clinical benefit of treatment may be only 
marginal. 
J. Westhuyzen, PhD a 
A. D. Cochrane, FRACS, FRCS (Cth) b 
Division of Chemical Pathology 
Royal Brisbane Hospital 
Brisbane 4029, Australia 
Victorian Paediatric Cardiac Surgical Unit 
Royal Children's Hospital 
Melbourne 3052, Australia b
12/8/84946 
Should intraaortic balloon counterpulsation be 
continued during cardiopulmonary bypass? 
To the Editor: 
We read with interest the article by Torchiana and 
associates 1 in the April 1997 issue of this Journal regard- 
ing trends in practice and outcome of intraaortic balloon 
(IAB) pumping for cardiac support. Using the strategy of 
preoperative insertion of the lAB, several other groups 
have also shown improvement in survival and reduced 
morbidity from perioperative infarction. 2-4 In many cen- 
ters an IAB is now electively inserted in the preoperative 
period for indications uch as evolving myocardial infarc- 
tion, refractory unstable angina, failed percutaneous 
transluminal ngioplasty necessitating emergency myocar- 
dial revascularization, complication of myocardial infarc- 
tion with cardiogenic shock, or redo operations. 3-5 Very 
little, however, is mentioned about the continuation of 
IAB counterpulsation during cardiopulmonary bypass 
(CPB). If an IAB has to be inserted before the cardiac 
operation is begun, we prefer to continue counterpulsa- 
tion throughout the operation. Counterpulsation is con- 
tinued even during the period of aortic crossclamping on 
th e intrinsic rate of the IAB and with 20% less than full 
augmentation. Once the heart starts ejecting, IAB coun- 
terpulsation can be synchronized with left ventricular 
diastole , unlike counterpulsation with conventional pulsa- 
tile pumps, to augment diastolic pumping and decrease 
systolic impedance. We temporarily stop the IAB pump 
only when clamping or unclamping the aorta. 
Many surgeons top IAB counterpulsation as soon as 
CPB is resumed, and counterpulsation is restarted while 
weaning the patient from CPB. We sent a questionnaire to
46 centers performing adult cardiac surgery in the United 
Kingdom and Ireland. From the 36 replies (78.2%) that 
we received, all surgeons at 29 centers (80.5%) stop IAB 
counterpu!sation  commencing CPB. At one center the 
IAB pump is set on minimum volume and frequency, 
mainly to reduce the risk of clotting. At the remaining six 
centers counterpulsation is continued uring CPB by all 
surgeons except one. It seems that not many surgeons 
make use of the potential advantages of having the IAB 
already in situ during CPB. 
IAB counterpulsation effectively minimizes ischemic 
myocardia 1 damage during induction of general anesthe- 
sia and during the pre-CPB period while conduits are 
being harvested, z' 6 On initiation of CPB, systemic perfu- 
sion is maintained with reduced pre!oad, which reduces 
myocardial oxygen needs significantly. The use of IAB 
